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ABSTRACT 
Sirtuin1 (SIRT1) and forkhead box transcription factor O subfamily 1 (FOXO1) play vital roles in the maintenance 
of hippocampal neuronal homeostasis during aging. Our previous study showed that melatonin, a hormone mainly 
secreted by the pineal gland, restored the impaired memory of aged mice. Age-related neuronal energy deficits 
contribute to the pathogenesis of several neurodegenerative disorders. An attempt has been made to determine 
whether the effect of melatonin is mediated through the SIRT1-FOXO1 pathways. The present results showed that 
aged mice (22 months old) exhibited significantly downregulated SIRT1, FOXO1, and melatonin receptors MT1 
and MT2 protein expression but upregulated tumor suppressor protein 53 (p53), acetyl-p53 protein (Ac-p53), 
mouse double minute 2 homolog (MDM2), Dickkopf-1 (DKK1) protein expression in mouse hippocampus com-
pared with the young group. Melatonin treatment (10 mg/kg, daily in drinking water for 6 months) in aged mice 
significantly attenuated the age-induced downregulation of SIRT1, FOXO1, MT1 and MT2 protein expression 
and attenuated the age-induced increase in p53, ac-p53, MDM2, and DKK1 protein and mRNA expression. Mel-
atonin decreased p53 and MDM2 expression, which led to a decrease in FOXO1 degradation. These present results 
suggest that melatonin may help the hippocampal neuronal homeostasis by increasing SIRT1, FOXO1 and mela-
tonin receptors expression while decreasing DKK1 expression in the aging hippocampus. DKK1 can be induced 
by the accumulation of amyloid β (Aβ) which is the major hallmark of Alzheimer’s disease. 
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INTRODUCTION 
Brain aging is linked to certain types of 
neurodegenerative diseases and has become 
critical for the identification of new therapeu-
tic targets. It is currently known that the 
pathological processes in aging brain are as-
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sociated with molecules and signaling path-
ways that sense and influence energy metab-
olism, e.g., sirtuins (SIRT1), forkhead box 
transcription factor O subfamily (FOXOs). 
SIRT1 and the FOXOs are the focus of many 
brain aging studies because of their interac-
tion with multiple target genes. The protec-
tive mechanisms of SIRT1 are closely related 
to many substrates. FOXOs, one of SIRT1 
targets, play a vital role in cellular homeosta-
sis. FOXO1 is highly expressed in the hippo-
campus and plays an important role in modu-
lating hippocampal neuronal homeostasis 
(Abbas et al., 2009). 
Tumor suppressor protein 53 (p53) is an-
other SIRT1 target that plays a vital role in the 
apoptosis pathway during aging. SIRT1 sup-
presses apoptosis through deacetylated p53 
and p53-related factors in many senescence 
models (Arunachalam et al., 2014; Engel and 
Mahlknecht, 2008; Rahman et al., 2012; 
Rodella et al., 2013). In addition, the p53 
pathway controls FOXOs expression. The 
mouse double minute 2 homolog (Mdm2) and 
the E3 ubiquitin-protein ligase are important 
negative autoregulators of p53. MDM2 binds 
to FOXO1 and FOXO3A and promotes their 
ubiquitination and subsequent degradation 
(Chung et al., 2015; Fu et al., 2009; Huang 
and Tindall, 2011). The Wnt/β-catenin path-
way regulates FOXO1 activities. In the nu-
cleus, β-catenin acts as a transcriptional co-
regulator with FOXOs, binding to specific 
DNA-binding transcription factors. There-
fore, -catenin enhances FOXO1 transcrip-
tional activity (Cadigan, 2008). Cellular oxi-
dative stress simultaneously increases bind-
ing between -catenin and FOXOs, which 
triggers stress response cascades (Purro et al., 
2014). 
Melatonin, a hormone mainly secreted by 
the pineal gland, is another anti-aging agent 
that could potentially be used to treat neuro-
degenerative diseases (Hardeland, 2013; 
Karasek, 2004, 2007). Our recent study 
showed that melatonin restored the impaired 
memory and attenuated the alteration of the 
amyloid precursor protein (APP) proteolytic 
processing enzyme (α- and β-secretases) ex-
pression in the hippocampus of aged mice 
(Mukda et al., 2016). Melatonin preserved the 
relative protein levels of SIRT1 in the senes-
cence-accelerated mice (SAMP8) (Cristofol 
et al., 2012; Gutierrez-Cuesta et al., 2008; 
Tajes Orduna et al., 2009) and in the hippo-
campus of total sleep-deprived rats (Chang et 
al., 2009). Age-related neuronal energy defi-
cits contribute to the pathogenesis of several 
neurodegenerative disorders, such as Alz-
heimer’s disease. Understanding of how mel-
atonin together with molecular, cellular and 
systemic energy metabolisms may lead to 
greater understanding of anti-aging mecha-
nisms to increase life span under healthy con-
dition. The present study aimed to answer 3 
questions. Firstly, whether melatonin pro-
moted FOXO1 expression and activities via 
an increase in SIRT1 expression, secondly, 
whether melatonin promoted FOXO1-β-
catenin activities through decreasing DKK1 
and thirdly, we also asked whether melatonin 
increased FOXO1 expression via a p53-
MDM2 interaction and decreased the degra-
dation of FOXO1. 
 
MATERIAL AND METHODS 
Animals 
Male mice (Mlac:ICR, outbreed, Mus 
musculus) used in the present experiment 
were obtained from the National Experi-
mental Animals Center of Mahidol Univer-
sity, Salaya Campus, Thailand. All animal 
procedures were approved through the Labor-
atory Animal Care and Use Committee of 
Mahidol University. We certify that we car-
ried out in accordance with the National Insti-
tute of Health Guide for the Care and Use of 
Laboratory Animals (NIH Publications No. 
80-23) revised 1996. All efforts were made to 
minimize the number of animals used and 
their suffering. The animals had free access to 
water and food and were maintained in a 12 h 
light/dark cycle (light on at 7.00 a.m.). The 
mice were divided into three treatment 
groups: (i) control young adult mice (2 
months of age, body weight = 30-35 g), (ii) 
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aged group (22 months old mice, body weight 
= 45-50 g), and (iii) aged mice + melatonin. 
Melatonin (Sigma Aldrich, St Louis, MO) so-
lution was freshly prepared daily. The long 
term melatonin-treated mice received melato-
nin in drinking water from 16 to 22 months of 
age (for a period of 6 months) according to 
our previous study protocol (Mukda et al., 
2016). The weight of each mouse and the 
amount of water containing melatonin intake 
for each mouse were measured. The daily 
melatonin intake for each mouse was approx-
imately 10 mg/kg (Cavallo and Hassan, 1995; 
Daya et al., 2001; Moussaoui and Bendriss, 
2014; Mukda et al., 2016). Control mice were 
continued on normal drinking water. At 22 
months of age, the mice were sacrificed, the 
brains were isolated and the hippocampus was 
dissected and stored at -80 °C until further 
use. 
 
Semi-quantitative reverse transcription 
PCR (RT-PCR) 
Total RNA was isolated using the TRI-
zolTM reagent (Invitrogen, Life Technologies, 
Carlsbad, CA, USA) according to the manu-
facturer’s protocol. RNA samples with suffi-
cient purity A260/A280 ratios at 1.8–2.0 were 
used for cDNA synthesis. Two microgram of 
total RNA was reverse transcribed by using 
reverse transcription kit (Promega, Madison, 
WI, USA) with an MJ Mini™ Gradient ther-
mal cycler (Bio-Rad, Hercules, CA, USA). 
PCR amplification was carried out using pri-
mer sets specific for SIRT1, FOXO1, p53, 
Mdm2, and Gapdh. The primer sequences are 
shown in Table 1. PCR amplification was car-
ried out at 95 °C for 40 s, 55 or 60 °C for 45 
s, and 72 °C for 50 s, which was repeated for 
30-35 cycles followed by incubation at 72 °C 
for 10 min. The amplified products were elec-
trophoresed on 1 % agarose gels in TBE buffer 
(89 mM Tris-base pH 7.6, 89 mM boric acid, 
2 mM EDTA). The gel was stained with Red-
SafeTM Nucleic Acid Stained (iNtRON, South 
Korea). The quantity and base pair size of the 
PCR products were estimated relative to 100 
bp DNA ladder marker (Thermo Fisher Scien-
tific Inc., Waltham, Massachusetts, USA). 
The gel images were photographed with an 
image analysis system (GelDoc 1000; Bio-
Rad, Hercules, CA, USA). Using the Gene 
Tools analysis software (Syngene, Cam-
bridge, UK), the intensities of specific PCR 
bands were quantified in relation to the 
Gapdh bands that were amplified from the 
same cDNA.  
 
Western blot analysis 
Protein extracts were prepared from tis-
sues samples mixed with lysis buffer 
(150 mM NaCl, 50 mM Tris-base, 1 mM phe-
nyl methanesulfonyl fluoride, 1 mM EDTA, 
1 % Triton X-100, 0.5 % sodium deoxycho-
late, 0.1 % SDS, 1 % protease inhibitor and 
1 % phosphatase inhibitor) and sonicated 
twice for 10 s each. The lysate was then cen-
trifuged at 12,000 x g for 15 min at 4 °C, and 
the supernatant was collected and used for 
Western blot analysis. Protein concentration 
was determined using the Bradford protein as-
say. Samples were denatured after adding 2X 
SDS sample buffer. Samples were electro-
phoresed on 10–12 % SDS–PAGE gels and 
transferred onto PVDF membranes. The 
membranes were blocked with blocking 
buffer for 1 h at room temperature and then 
incubated overnight at 4 °C with different an-
tibodies as shown in Table 2; mouse mono-
clonal antibody against SIRT1 (1:2,000), rab-
bit polyclonal antibody against FOXO1 
(1:2,000), rabbit polyclonal antibody against 
DKK1 (1:2,000), mouse monoclonal anti-
body against MDM2 (1:2,000), rabbit poly-
clonal antibody against p53 (1:2,000), and 
rabbit polyclonal antibody against acetylated 
p53 (Lys 379) (1:2,000). All antibodies were 
diluted using Can Get Signal™. After wash-
ing three times with TBST, the membranes 
were incubated with anti-mouse IgG antibody 
(1:5,000), or anti-ra:bit IgG antibody 
(1:5,000). The membranes were washed three 
times with Tris-Buffered Saline and Tween 
20 (TBST) and processed for chemilumines-
cence detection using ECL Plus™. Western 
blotting detection reagents were added, and 
EXCLI Journal 2017;16:340-353 – ISSN 1611-2156 
Received: December 21, 2016, accepted: March 01, 2017, published: March 23, 2017 
 
 
343 
the membrane was exposed using the Azure 
c300 Chemiluminescent Western Blot Imag-
ing System™ (Azure Biosystems, Inc., Dub-
lin, CA, USA). The immunoblot band densi-
ties were quantified using a densitometer with 
the Scion image program (National Institutes 
of Health, Bethesda, MD). 
 
 
 
Table 1: Primer sequences for semi-quantitative RT-PCR 
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Table 2: The antibodies used for Western blotting 
 
 
Statistical analysis 
The data are expressed as means ± S.E.M. 
Significance was assessed using one-way 
analysis of variance (ANOVA), followed by 
Tukey–Kramer post-hoc tests, using Graph-
Pad Prism version 5. P-values less than 0.05 
were considered significant. 
 
RESULTS 
SIRT1 and FOXO1 protein and mRNA  
expressions in the aged hippocampus 
SIRT1 protein and mRNA expression 
were significantly decreased in the aged hip-
pocampus when compared to the expression 
in young mice. The melatonin-treated group 
significantly increased SIRT1 protein and 
mRNA expression in aged mice compared 
with the aged untreated group (Figures 1A, 
B). FOXO1 protein and mRNA expression 
were significantly decreased in aged mice. 
The melatonin-treated group significantly up-
regulated FOXO1 protein and mRNA expres-
sion in the hippocampus of aged mice when 
compared with the aged control group 
(Figures 2A, B).  
 
p53 protein and mRNA expressions in the 
aged hippocampus 
Because the p53-MDM2 regulatory path-
way can modulate FOXO1 expression, we de-
termined the effect of melatonin on p53 ex-
pression in the hippocampus of aged mice. 
Protein and mRNA expression of p53 in aged 
hippocampus significantly increased when 
compared to the young control group. Mela-
tonin significantly decreased p53 protein and 
mRNA expression levels compared with 
those seen in the aged control group (Figures 
3 A, B). Because p53 is a SIRT1 target, we 
explored SIRT1 activity by detecting the acet-
ylated form of p53. Ac-p53 protein expres-
sion in aged mice was higher than that seen in 
the young control group. Melatonin signifi-
cantly attenuated the increase in Ac-p53 ex-
pression in aged mice compared to the aged 
control group (Figure 3 C). 
 
MDM2 protein and mRNA expressions in 
the aged hippocampus 
We determined whether MDM2, an ubiq-
uitin E3 ligase for p53, can degrade FOXO1. 
Protein and mRNA expression levels of 
Mdm2 in the aged hippocampus were signifi-
cantly increased when compared to the ex-
pression seen in the hippocampus of young 
mice. Melatonin treatment of the aged group 
significantly decreased MDM2 protein and 
mRNA expression compared with the expres-
sion levels in the aged control group (Figures 
4A, B). The result suggested that the ubiquiti-
nation of FOXO1 in the aged hippocampus 
might be due to the activity of MDM2.  
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Figure 1: The effect of melatonin on sirtuin1 
(SIRT1) protein (A) and mRNA (B) expression in 
the aging mouse hippocampus. SIRT1 protein ex-
pression in the hippocampus was compared be-
tween young and aged mice. Aged mice were 
treated with drinking water or with melatonin (Mel) 
at 10 mg/kg/day for 6 months. Representative 
bands from the different groups are shown. The 
bands from the semi-quantitative PCR were nor-
malized to Gapdh, whereas the band densities 
from the Western blots were normalized to actin. 
The ratios were calculated as a percentage of the 
respective value of the control group. The values 
represent means ± SEM (n=4 for each group). (* 
and ** denote significant differences with p < 0.05 
and p < 0.01, respectively, compared with young 
control group, and # denotes a significant differ-
ence with p < 0.05 compared with the aged control 
group). 
 
 
Figure 2: The effect of melatonin on FOXO1 pro-
tein (A) and mRNA (B) expression in the aging 
mouse hippocampus. The protein expression of 
FOXO1 was compared between young and aged 
mice. Aged mice were treated with drinking water 
or with melatonin (Mel) at 10 mg/kg/day for 6 
months. Representative bands from the different 
groups are shown. The bands from the semi-
quantitative PCR were normalized to Gapdh, 
whereas the band densities from the Western 
blots were normalized to actin. The ratios were 
calculated as a percentage of the respective value 
of the control group. The values represent means 
± SEM (n=4 for each group). (* denotes a signifi-
cant difference with p < 0.05 compared with the 
young control group, and # denotes a significant 
difference with p < 0.05 compared with the aged 
control group). 
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Figure 3: The effect of melatonin on p53 protein 
expression (A), p53 mRNA expression (B) and 
the acetylated form of p53 protein expression (C) 
in the aging mouse hippocampus. Aged mice 
were treated with drinking water or melatonin 
(Mel) at 10 mg/kg/day for 6 months. Representa-
tive bands from the different groups are shown. 
The bands from the semi-quantitative PCR were 
normalized to Gapdh, whereas the band densities 
from the Western blots were normalized to actin. 
The ratios were calculated as a percentage of the 
respective value of the control group. The values 
represent means ± SEM (n=4 for each group (* 
denotes a significant difference with p < 0.05 com-
pared with the young control group, and # denotes 
a significant difference with p < 0.05 compared 
with the aged control group). 
 
 
 
Figure 4: The effect of melatonin on MDM2 pro-
tein (A) and mRNA (B) expression in the aging 
mouse hippocampus. Aged mice were treated 
with drinking water or melatonin (Mel) at 10 
mg/kg/day for 6 months. Representative bands 
from the different groups are shown. The bands 
from the semi-quantitative PCR were normalized 
to Gapdh, whereas the band densities from the 
Western blots were normalized to actin. The ratios 
were calculated as a percentage of the respective 
value of the control group. The values represent 
means ± SEM (n=4 for each group). (* denotes a 
significant difference with p < 0.05 compared with 
the young control group, and # denotes a signifi-
cant difference with p < 0.05 compared with the 
aged control group). 
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DKK1 protein and mRNA expressions in 
the aged hippocampus 
DKK1, a specific negative modulator of 
the Wnt pathway, was investigated in this 
study to determine whether the melatonin-in-
duced increase in FOXO1 activity occurs via 
the Wnt/β-catenin pathway. The results 
showed that DKK1 protein and mRNA levels 
in the aged hippocampus were significantly 
increased when compared to those seen in the 
young group. The melatonin-treated group 
significantly decreased DKK1 protein and 
mRNA expression when compared to the lev-
els seen in the aged control group (Figures 
5A, B).  
 
MT1 and MT2 melatonin receptors proteins 
in the aged hippocampus 
The levels of melatonin receptors MT1 
and MT2 were examined (Figures 6A, B). In 
aging hippocampus, MT1 and MT2 levels 
were significantly downregulated when com-
pared to those seen in the young group. Mel-
atonin was able to significantly restore the re-
duction of melatonin receptors in the aged 
group.  
 
DISCUSSION 
In the present study it has been shown that 
SIRT1 was downregulated in the aged hippo-
campus, while melatonin treatment for 6 
months restored SIRT1 expression. Previous 
studies demonstrated that melatonin in-
creased SIRT1 expression in a variety of 
models (Chang et al., 2009; Tajes et al., 
2009). Melatonin protected neurons by pre-
serving protein levels of SIRT1 in the dentate 
gyrus of aged rats (Kireev et al., 2013), a total 
sleep-deprived model (Chang et al., 2009), 
SAMP8 mice (Cristofol et al., 2012; 
Gutierrez-Cuesta et al., 2008; Tajes et al., 
2009) and neonatal rats subjected to hypoxia-
ischemia (Carloni et al., 2014). SIRT1 is 
NAD+-dependent deacetylase that senses 
changes in intracellular NAD+ levels (Canto 
and Auwerx, 2012), the supportive effect of 
melatonin on SIRT1 may act via the nicotina-
mide adenine dinucleotide (NAD) system. 
Melatonin, an effective antioxidant, preserves 
NAD levels under oxidative stress. When 
melatonin was incubated with the PC12 cell 
line in an oxidative environment, the oxida-
tion was reduced and melatonin donated an 
electron to the NAD radical, resulting in the 
generation of NAD (Tan et al., 2005). 
 
Figure 5: The effect of melatonin on DKK1 protein 
(A) and mRNA (B) expression in the aging mouse 
hippocampus. Aged mice were treated with drink-
ing water or melatonin (Mel) at 10 mg/kg/day for 6 
months. The representative bands from the differ-
ent groups are shown. The bands from the semi-
quantitative PCR were normalized to Gapdh, 
whereas the band densities from the Western 
blots were normalized to actin. The ratios were 
calculated as a percentage of the respective value 
of the control group. The values represent means 
± SEM (n=4 for each group). (* denotes a signifi-
cant difference with p < 0.05 compared with the 
young control group, and # denotes a significant 
difference with p < 0.05 compared with the aged 
control group). 
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Figure 6: The effect of melatonin on MT1 (A) and 
MT2 (B) expression in the aging mouse hippo-
campus. Aged mice were treated with drinking 
water or melatonin (Mel) at 10 mg/kg/day for 6 
months. The representative bands from the differ-
ent groups are shown. The band densities from 
the Western blots were normalized to actin. The 
ratios were calculated as a percentage of the re-
spective value of the control group. The values 
represent means ± SEM (n=4 for each group). (** 
denotes significant difference with p < 0.01, com-
pared with the young control group, # and ## de-
note significant difference with p < 0.05 and p < 
0.01 compared with the aged control group). 
 
 
We found that FOXO1 was downregu-
lated by aging, and the reduction could be pre-
vented by melatonin administration. FOXO1 
was predominantly expressed in the hippo-
campus and declined during aging (Zemva et 
al., 2012). Melatonin may increase FOXO1 
expression through the PI3K/Akt pathway. In 
an aged neuronal cell culture, melatonin in-
creased Akt activation, leading to GSK3 in-
hibition and an increase in FOXO1 phosphor-
ylation (Tajes et al., 2009). Melatonin had 
protective effects against brain injury through 
activating Akt and its downstream targets in a 
middle cerebral artery occlusion model (Koh, 
2008). Melatonin increased the interaction of 
phosphorylated-FOXO1 (p-FOXO1) and 14-
3-3 in a kainic acid-induced hippocampal ex-
citotoxicity model (Lee et al., 2006) and in fo-
cal cerebral ischemia in rats (Zheng et al., 
2014). The acetylation of FOXO1 decreased 
DNA binding and FOXOs activity (Bousiges 
et al., 2010; Wang et al., 2012). Melatonin up-
regulated the expression of SIRT1 and down-
regulated the expression of ac-FOXO1 in a 
cecal ligation brain injury model (Zhao et al., 
2015). Melatonin not only promotes FOXOs 
activities via SIRT1 deacetylation but also 
acts through CREB-binding protein (CBP) 
and p300. Melatonin suppressed p300 histone 
acetyltransferase (HAT) activity and p300 
HAT-mediated NF-κB acetylation in the hu-
man vascular smooth muscle cell line 
CRL1999 (Shi et al., 2012). 
In the present study, melatonin treatment 
in aged animal decreased p53, acetyl-p53 
compared with aged mice. This ameliorated 
the FOXO1 degradation process. Melatonin 
decreased p53 both in in vitro and in vivo 
studies (Gutierrez-Cuesta et al., 2008). SIRT1 
expression was lower in SAMP8 mice com-
pared with SAMR1 mice, and these changes 
were prevented by melatonin (Gutierrez-
Cuesta et al., 2008). In a neuronal cell culture, 
melatonin treatment inhibited the Ataxia tel-
angiectasia mutated (ATM) protein. ATM is 
a serine/threonine protein kinase that phos-
phorylates several key proteins that initiate 
the activation of the DNA damage check-
point, including p53 and MDM2. Moreover, 
melatonin administration activated the pro-
survival protein Akt, which resulted in GSK-
3β inhibition and an increase in p-FOXO1 
(Tajes et al., 2009).  
p53 activation is mainly regulated by 
MDM2 in the nucleus. MDM2 also acts as E3 
EXCLI Journal 2017;16:340-353 – ISSN 1611-2156 
Received: December 21, 2016, accepted: March 01, 2017, published: March 23, 2017 
 
 
349 
ubiquitin ligase, promoting proteasome-de-
pendent p53 degradation; therefore, p53 and 
MDM2 regulate each other in an autoregula-
tory loop. Melatonin drastically downregu-
lated Mdm2 gene expression and inhibited 
MDM2 shuttling into the nucleus of MCF7 
breast cancer cells. Because PI3K/Akt-medi-
ated MDM2 phosphorylation on serine 166 is 
essential to enable MDM2 entry in the nu-
cleus, melatonin slowed down the activity of 
the PI3K/AkT pathway, leading to a reduction 
in MDM2 levels. In addition, the inhibition of 
Akt-mediated MDM2 phosphorylation pre-
vents the nuclear translocation of MDM2 and 
consequently impairs its ability to target and 
degrade p53 (Proietti et al., 2011, 2014). Both 
MDM2 and p53 graphs showed the same 
trend of expression in the present results, 
since P53 and MDM2 regulate each other in 
an autoregulatory feedback loop. If the ex-
pression of MDM2 or p53 is out of the auto-
regulatory manner, this will trigger the DNA 
damage (Pant et al., 2013). 
The neuroprotective effects of melatonin 
may be due to a decrease in the acetylated 
form of p53. The acetylation of p53 on some 
residues such as lysine373, enhanced the sta-
bilization/activity of p53 and increased the 
susceptibility of cells to stress. Acetylation of 
p53 was altered in the hippocampus following 
global cerebral ischemia (Raz et al., 2011). In 
addition, the acetylated form of p53 attenu-
ated mdm2-mediated ubiquitination, possibly 
through inducing a protein conformational 
change (Ito et al., 2002; Li et al., 2002). 
To investigate whether melatonin affects 
Wnt/β-catenin signaling, we determined the 
expression of the specific inhibitor Dickkopf-
1 (DKK1). We found that DKK1 protein and 
mRNA levels in the aged hippocampus were 
higher than those in the young group, and 
melatonin treatment lowered the level of 
DKK1 protein and mRNA. DKK1 is a spe-
cific inhibitor of the Wnt pathway, and antag-
onizes signaling by binding to low-density 
lipoprotein receptor-related protein 5/6 
(LRP5/6). DKK1 is scarcely found in normal 
brain, but upregulation of DKK1 precedes 
neuronal death in models of neurodegenera-
tive diseases (Caricasole et al., 2004; Rosi et 
al., 2010) and ischemic neuronal death 
(Cappuccio et al., 2005). Melatonin may de-
crease DKK1 via downregulation of p53. 
DKK1 is induced by p53 because the Dkk1 
transcription start site has a p53 responsive el-
ement (Caricasole et al., 2004; Wang et al., 
2000), whereas DKK1 and Wnt inhibitory 
factor-1 (WIF1) significantly activated the 
transcription of p53 in ovarian carcinoma 
cells (Ko et al., 2014). In addition, mature 
neurons exposed to DKK1 showed a decrease 
in the number of functional synaptic vesicle 
recycling sites, and DKK1 promoted the dis-
persion of pre- and postsynaptic proteins, in-
dicating a loss of synapses (Purro et al., 
2014). The inhibition of the Wnt pathway in 
neurospheres by retroviral overexpression of 
Dkk1 robustly increased gliogenesis at the ex-
pense of neurogenesis (Kunke et al., 2009). 
Aging rat hippocampus exhibited an upregu-
lation of DKK1, while exercise could reverse 
this change in expression. 
Several lines of evidence have suggested 
a pathophysiological relationship between re-
duction in melatonin and melatonin receptors 
with aging and neurodegenerative diseases. 
Our result here showed that MT1 and MT2 
declined during aging while melatonin sup-
plement was able to reverse this change. Mel-
atonin transmits its action via the specific 
high affinity G-protein couple receptors 
(Reppert et al., 1994) which are expressed in 
several areas of the brain, including hippo-
campus (Mazzucchelli et al., 1996). Melato-
nin exerts its action on neurogenesis via the 
membrane-bound receptor both in the sub-
ventricular zone (Sotthibundhu et al., 2010) 
and rat hippocampus (Tocharus et al., 2014). 
In this study, we found an increase in MT1 
and MT2 protein levels after melatonin treat-
ment, which is consistent with our previous 
studies in cultured adult subventricular zone 
neurospheres (Sotthibundhu et al., 2010) and 
in cultured adult hippocampal precursor cells 
pretreated with dexamethasone (Ekthuwa-
pranee et al., 2015). Activation of MT1 via 
Gαi-coupled melatonin receptors has been 
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shown to produce the inhibitory responses in 
the cAMP signal transduction cascade, result-
ing in decreases in PKA activity and in CREB 
phosphorylation (Brydon et al., 1999; Dubo-
covich et al., 2003; Li et al., 1998). Moreover, 
through the dissociation of β subunits of Gi, 
melatonin activates MAP kinases as well as 
the Ras-MEK pathway to stimulate ERK 
phosphorylation (Carbajo-Pescador et al., 
2011; Pearson et al., 2001; Witt-Enderby et 
al., 2003). Activation of the MT2 can also re-
sult in decreases in cGMP, decreases cAMP 
formation and PI hydrolysis via Gαi subunit 
activation (Dubocovich et al., 2010; 
Markowska et al., 2004). Melatonin acted 
through MT1 and MT2 receptors to activate 
hypothalamic Akt/PKB and protein kinase B 
to suppress hepatic gluconeogenesis in rats 
(Faria et al., 2013). 
Aging decreases the Wnt pathway activi-
ties. Melatonin may help to enhance the Wnt 
pathway through different pathways. For ex-
ample; melatonin decreased reactive oxygen 
species (ROS) and decreased GSK-3. In-
creases in GSK-3 activity during aging inac-
tivate -catenin through phosphorylation. 
Melatonin increased phosphorylated GSK-3 
in primary cultures of cerebellar granule neu-
rons (Tajes et al., 2009), in a SAMP8 mice ag-
ing model (Gutierrez-Cuesta et al., 2007) and 
in an Alzheimer's animal model (Kwon et al., 
2010; Peng et al., 2013). Melatonin may act 
through PI3K-Akt-GSK3 pathway via MT1 
and MT2 receptors. In addition, melatonin de-
creases some factors that are related to neuro-
degenerative diseases, such as amyloid  
(A) since A accumulation induces Dkk1 
production. 
 
CONCLUSION 
In summary, the current study suggested 
possible mechanisms of the neuroprotective 
effects of melatonin on the FOXO1 pathway 
during aging. Melatonin significantly upregu-
lated SIRT1, FOXO1, MT1 and MT2 expres-
sion but downregulated p53, ac-p53 and 
MDM2, the ligase enzyme that ubiquitinates 
FOXO1. Melatonin may increase FOXO1 ex-
pression via downregulation of the p53-
MDM2 pathway. The expression of DKK1, a 
specific inhibitor of the canonical Wnt path-
way, was downregulated by melatonin. Mela-
tonin may promote FOXO1 activities by in-
ducing β-catenin, the co-transcription factor 
of FOXO1.  
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